LAUR Repository

Show simple item record

dc.contributor.author Ramadan, Wijdan H.
dc.contributor.author Kabbara, Wissam K.
dc.date.accessioned 2016-10-03T09:15:48Z
dc.date.available 2016-10-03T09:15:48Z
dc.date.issued 2016-10-03
dc.identifier.issn 1176-6344 en_US
dc.identifier.uri http://hdl.handle.net/10725/4485
dc.description.abstract Background The purpose of this study was to review the current literature and information on the combination product Juvisync™ (sitagliptin + simvastatin), which was approved by the US Food and Drug Administration in October 2011. Methods PubMed (2001–2014) was searched for primary and review articles on sitagliptin, simvastatin, or the combination product. Drug manufacturing data and product labeling were also used. Studies of simvastatin, sitagliptin, or the combination were screened and analyzed to include relevant and recent papers. Selected English language trials were limited to those with human subjects and included both safety and efficacy outcomes. Results When compared with glipizide as add-on therapy to metformin, sitagliptin was noninferior but had lower rates of hypoglycemia and weight gain. In addition, when compared with insulin glargine, sitagliptin was less effective in decreasing glycosylated hemoglobin, but was associated with significantly lower rates of hypoglycemia. Further, trials have shown a beneficial effect of using statins in patients with diabetes mellitus with regard to decreasing cardiovascular risk, regardless of baseline lipid levels or the presence of a cardiac disease. Both medications have also demonstrated an acceptable side effect profile. However, caution is needed when coadministering with any drug that may increase simvastatin levels to reduce the risk of myopathy and rhabdomyolysis. Conclusion Juvisync should be used in patients requiring both sitagliptin and simvastatin. Both agents have shown good efficacy and acceptable safety profiles. Sitagliptin is a good option for diabetic patients to improve glycemic control with a lower risk of hypoglycemia and weight gain. en_US
dc.language.iso en en_US
dc.title Sitagliptin/Simvastatin en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle a first combination tablet to treat type 2 diabetes and hypercholesterolemia – a review of its characteristics en_US
dc.author.school SOP en_US
dc.author.idnumber 200104485 en_US
dc.author.department Pharmacy Practice Department en_US
dc.description.embargo N/A en_US
dc.relation.journal Vascular Health and Risk Management en_US
dc.journal.volume 2015 en_US
dc.journal.issue 11 en_US
dc.article.pages 125-132 en_US
dc.keywords Simvastatin en_US
dc.keywords Sitagliptin en_US
dc.keywords Juvisync™ en_US
dc.keywords Diabetes mellitus en_US
dc.keywords Hypercholesterolemia en_US
dc.identifier.doi http://dx.doi.org/ 10.2147/VHRM.S79198 en_US
dc.identifier.ctation Ramadan, W. H., & Kabbara, W. K. (2015). Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia–a review of its characteristics. Vascular health and risk management, 11, 125. en_US
dc.author.email wissam.kabbara@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334171/ en_US
dc.orcid.id https://orcid.org/0000-0002-7310-9192 en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account